Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Pierre Pignon

Showing results (81-90 of 144) with videos related to

Pageof 15
Sort By:
The Lancet. Oncology|February 28, 2009
Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient dataStefan Michiels, Aurélie Le Maître, Marc Buyse, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2008
Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small-cell lung cancerMartin Früh, Estelle Rolland, Jean-Pierre Pignon, et al.
The American Journal of Pathology|January 13, 2011
ERCC1 and RRM1 in the international adjuvant lung trial by automated quantitative in situ analysisGerold Bepler, Ken André Olaussen, Anne-Lise Vataire, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 23, 2009
Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer: subgroup analysis of the Lung Adjuvant Cisplatin EvaluationJean-Yves Douillard, Hélène Tribodet, Delphine Aubert, et al.
Clinical Lung Cancer|January 26, 2019
Clinical Relevance of EGFR- or KRAS-mutated Subclones in Patients With Advanced Non-small-cell Lung Cancer Receiving Erlotinib in a French Prospective Cohort (IFCT ERMETIC2 Cohort - Part 2)Michèle Beau-Faller, Matthieu Texier, Hélène Blons, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 26, 2009
Long-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected lung cancerRodrigo Arriagada, Ariane Dunant, Jean-Pierre Pignon, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 17, 2012
A pooled exploratory analysis of the effect of tumor size and KRAS mutations on survival benefit from adjuvant platinum-based chemotherapy in node-negative non-small cell lung cancerSinead Cuffe, Abderrahmane Bourredjem, Stephen Graziano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 4, 2007
Multidrug resistance proteins do not predict benefit of adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: International Adjuvant Lung Cancer Trial Biologic ProgramMartin Filipits, Vincent Haddad, Katharina Schmid, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|July 17, 2014
Radiation plus docetaxel and cisplatin in locally advanced pancreatic carcinoma: a non-comparative randomized phase II trialMichel Ducreux, Marc Giovannini, Charlotte Baey, et al.
Anti-Cancer Drugs|April 2, 2004
Adjusting for patient selection suggests the addition of docetaxel to 5-fluorouracil-cisplatin induction therapy may offer survival benefit in squamous cell cancer of the head and neckJean-Pierre Pignon, Nathalie Syz, Marshall Posner, et al.
Pageof 15

Showing results (81-90 of 144) with videos related to

Sort By:
Pageof 15
The Lancet. Oncology|February 28, 2009
Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient dataStefan Michiels, Aurélie Le Maître, Marc Buyse, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2008
Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small-cell lung cancerMartin Früh, Estelle Rolland, Jean-Pierre Pignon, et al.
The American Journal of Pathology|January 13, 2011
ERCC1 and RRM1 in the international adjuvant lung trial by automated quantitative in situ analysisGerold Bepler, Ken André Olaussen, Anne-Lise Vataire, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 23, 2009
Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer: subgroup analysis of the Lung Adjuvant Cisplatin EvaluationJean-Yves Douillard, Hélène Tribodet, Delphine Aubert, et al.
Clinical Lung Cancer|January 26, 2019
Clinical Relevance of EGFR- or KRAS-mutated Subclones in Patients With Advanced Non-small-cell Lung Cancer Receiving Erlotinib in a French Prospective Cohort (IFCT ERMETIC2 Cohort - Part 2)Michèle Beau-Faller, Matthieu Texier, Hélène Blons, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 26, 2009
Long-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected lung cancerRodrigo Arriagada, Ariane Dunant, Jean-Pierre Pignon, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 17, 2012
A pooled exploratory analysis of the effect of tumor size and KRAS mutations on survival benefit from adjuvant platinum-based chemotherapy in node-negative non-small cell lung cancerSinead Cuffe, Abderrahmane Bourredjem, Stephen Graziano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 4, 2007
Multidrug resistance proteins do not predict benefit of adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: International Adjuvant Lung Cancer Trial Biologic ProgramMartin Filipits, Vincent Haddad, Katharina Schmid, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|July 17, 2014
Radiation plus docetaxel and cisplatin in locally advanced pancreatic carcinoma: a non-comparative randomized phase II trialMichel Ducreux, Marc Giovannini, Charlotte Baey, et al.
Anti-Cancer Drugs|April 2, 2004
Adjusting for patient selection suggests the addition of docetaxel to 5-fluorouracil-cisplatin induction therapy may offer survival benefit in squamous cell cancer of the head and neckJean-Pierre Pignon, Nathalie Syz, Marshall Posner, et al.
Pageof 15